Kusterlab
@kusterlab.bsky.social
If you're a KRAS nerd, get your holistic view of oncogenic KRAS signaling here: www.science.org/doi/10.1126/...
#KRAS #proteomics (4/4)
#KRAS #proteomics (4/4)
Proteomic analyses identify targets, pathways, and cellular consequences of oncogenic KRAS signaling
Proteomic analyses offer insights into how KRAS inhibitors affect oncogenic KRAS signaling.
www.science.org
July 31, 2025 at 8:10 AM
If you're a KRAS nerd, get your holistic view of oncogenic KRAS signaling here: www.science.org/doi/10.1126/...
#KRAS #proteomics (4/4)
#KRAS #proteomics (4/4)
What makes it even better: All experiments were performed in a dose-resolved manner—so you can dive into dose-response curves in our interactive dashboards! #CurveCurator #BeautifulCurves (3/4)
July 31, 2025 at 8:10 AM
What makes it even better: All experiments were performed in a dose-resolved manner—so you can dive into dose-response curves in our interactive dashboards! #CurveCurator #BeautifulCurves (3/4)
We explore how inhibition of oncogenic KRAS signaling reshapes protein phosphorylation, ubiquitylation, and protein expression—across multiple time points, using various KRAS inhibitors, as well as upstream and downstream pathway inhibitors, in different KRAS-mutant cell lines. (2/4)
July 31, 2025 at 8:10 AM
We explore how inhibition of oncogenic KRAS signaling reshapes protein phosphorylation, ubiquitylation, and protein expression—across multiple time points, using various KRAS inhibitors, as well as upstream and downstream pathway inhibitors, in different KRAS-mutant cell lines. (2/4)
📢 Read the full paper here: doi.org/10.1038/s44320-025-00085-6 – we’d love to hear your thoughts! #CancerResearch #PDAC #MolecularBiology #Proteomics (4/4)
Gemcitabine and ATR inhibitors synergize to kill PDAC cells by blocking DNA damage response | Molecular Systems Biology
imageimagePhosphoproteomics unveils the mode of action of clinical ATR inhibitors and explains
their synergy with Gemcitabine in pancreatic cancer cells. Viability screening of 146 targeted drugs ide...
doi.org
March 4, 2025 at 4:06 PM
📢 Read the full paper here: doi.org/10.1038/s44320-025-00085-6 – we’d love to hear your thoughts! #CancerResearch #PDAC #MolecularBiology #Proteomics (4/4)
🔎 To uncover the molecular mechanisms driving this synergy, we employed both chemo- and phosphoproteomics (decryptM), which revealed how ATR inhibition disrupts the DNA damage response when combined with gemcitabine. (3/4)
March 4, 2025 at 4:06 PM
🔎 To uncover the molecular mechanisms driving this synergy, we employed both chemo- and phosphoproteomics (decryptM), which revealed how ATR inhibition disrupts the DNA damage response when combined with gemcitabine. (3/4)
🧫 Using large-scale phenotypic drug screening, we identified promising drug combinations that enhance tumor cell death - and found Gemcitabine and ATR inhibitors to synergize most effectively. (2/4)
March 4, 2025 at 4:06 PM
🧫 Using large-scale phenotypic drug screening, we identified promising drug combinations that enhance tumor cell death - and found Gemcitabine and ATR inhibitors to synergize most effectively. (2/4)
Our tool was built using Vue.js and D3.js and is free for public reuse (github.com/kusterlab/bi..., github.com/wilhelm-lab/...).
Thanks to everyone involved! 🥳 We're looking forward to seeing how it'll be received by the community. (6/6).
Thanks to everyone involved! 🥳 We're looking forward to seeing how it'll be received by the community. (6/6).
January 10, 2025 at 2:20 PM
Our tool was built using Vue.js and D3.js and is free for public reuse (github.com/kusterlab/bi..., github.com/wilhelm-lab/...).
Thanks to everyone involved! 🥳 We're looking forward to seeing how it'll be received by the community. (6/6).
Thanks to everyone involved! 🥳 We're looking forward to seeing how it'll be received by the community. (6/6).